The Center for Disease Detection’s (CDD) core business is centered around implementation of automated, high-volume, integrated diagnostic solutions for public health authorities such as the US Department of Labor, US Department of Defense, and US state Departments of Health.
CDD accomplishes this through streamlined and integrated laboratory processes and workflows, which allow for high-volume, high-quality service, with a simplified client interface. Moreover, CDD owns the best testing equipment available, and our personnel are proficient in the use of the most accurate methodologies. We know how to manage testing, data, and statistics; and we provide responsive customer service.
The Center for Disease Detection personnel are skilled in infectious disease testing. CDD is the single-largest human immunodeficiency virus (HIV)-diagnostic facility in the US. Additionally, we process large volumes of chlamydia/gonorrhea, hepatitis, syphilis, human papillomavirus (HPV), and herpes simplex virus (HSV) testing, through a variety of methods. On average, CDD reports over 99% of its results within the same day of specimen receipt. Furthermore, our laboratory information system allows for automatic transmission of results to our clients.
CDD’s clients include Family Planning and Reproductive Health Organizations. CDD personnel are able to provide a myriad of testing options for cytology, anatomic pathology, and infectious agents screening for women’s health purposes. CDD utilizes BD SurePath™, HOLOGIC® ThinPrep, and IncellDx OncoTect methods as well as Roche cobas® HPV testing for cervical cytology screening. Our pathologists are experienced in interpretation of biopsies of the uterine cervix (including loop electrosurgical excision and conization procedures), vulva, vagina, endometrium, as well as endocervical samplings, products of conception, and breast smears.
CDD offers comprehensive toxicology services, with drug panel options to screen for a wide variety of both illegal and frequently abused prescription drugs. Screens are performed using a sophisticated chemistry analyzer utilizing the Enzyme Immunoassay (EIA) method. This method allows for accurate screening with reduced cross-reacting substances. Confirmations for positive screens of the most commonly abused illegal substances are performed and results reported within 24 hours of positive screen.
CDD has four resident (full-time) pathologists and consulting pathologists available, as-needed. In this regard, CDD is ready-to-assist with fast, reliable, interpretation of cytology and anatomic pathology specimens.